CA2358508A1 - Applications therapeutiques de polypeptides flint - Google Patents

Applications therapeutiques de polypeptides flint Download PDF

Info

Publication number
CA2358508A1
CA2358508A1 CA002358508A CA2358508A CA2358508A1 CA 2358508 A1 CA2358508 A1 CA 2358508A1 CA 002358508 A CA002358508 A CA 002358508A CA 2358508 A CA2358508 A CA 2358508A CA 2358508 A1 CA2358508 A1 CA 2358508A1
Authority
CA
Canada
Prior art keywords
mflint
cells
arg
flint
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002358508A
Other languages
English (en)
Inventor
Fredric Jay Cohen
James Arthur Posada
Daniel Wierda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US1999/006797 external-priority patent/WO1999050413A2/fr
Application filed by Individual filed Critical Individual
Publication of CA2358508A1 publication Critical patent/CA2358508A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

la protéine FLINT mature (mFLINT) se lie avec FasL et LIGHT, et empêche une interaction FasL-Fas. La protéine mature mFLINT inhibe l'activité apoptotique et pro-inflammatoire à médiation FasL-Fas, et convient pour le traitement de troubles associés à une apoptose et à une inflammation anormales. L'invention concerne des séquences d'amino-acides et de nucléotides de FLINT et de FLINT mature. Elle porte également sur des compositions thérapeutiques et sur des méthodes de traitement faisant intervenir mFLINT.
CA002358508A 1998-12-22 1999-12-21 Applications therapeutiques de polypeptides flint Abandoned CA2358508A1 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US11340798P 1998-12-22 1998-12-22
US60/113,407 1998-12-22
PCT/US1999/006797 WO1999050413A2 (fr) 1998-03-30 1999-03-30 APPLICATIONS THERAPEUTIQUES DE POLYPEPTIDES mFLINT MURS, OU DE OPG3 EN TANT QUE MEMBRE DE LA SUPERFAMILLE DU RECEPTEUR DU TNF
USPCT/US99/06797 1999-03-30
US17223999P 1999-10-20 1999-10-20
US60/172,239 1999-10-20
PCT/US1999/030734 WO2000037094A2 (fr) 1998-12-22 1999-12-21 Applications therapeutiques de polypeptides flint

Publications (1)

Publication Number Publication Date
CA2358508A1 true CA2358508A1 (fr) 2000-06-29

Family

ID=27378725

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002358508A Abandoned CA2358508A1 (fr) 1998-12-22 1999-12-21 Applications therapeutiques de polypeptides flint

Country Status (5)

Country Link
EP (1) EP1140138A2 (fr)
JP (1) JP2003520761A (fr)
AU (1) AU2211100A (fr)
CA (1) CA2358508A1 (fr)
WO (1) WO2000037094A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69837996T2 (de) 1997-01-14 2008-02-28 Human Genome Sciences, Inc. Tumornekrosefaktor-rezeptoren 6 alpha& 6 beta
US7285267B2 (en) 1997-01-14 2007-10-23 Human Genome Sciences, Inc. Tumor necrosis factor receptors 6α & 6β
WO2002009668A2 (fr) * 2000-08-02 2002-02-07 Eli Lilly And Company Administration de flint (proteine inhibitrice du ligand fas) par voie pulmonaire
GB202016058D0 (en) * 2020-10-09 2020-11-25 Ucl Business Ltd Therapeautic treatment

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69837996T2 (de) * 1997-01-14 2008-02-28 Human Genome Sciences, Inc. Tumornekrosefaktor-rezeptoren 6 alpha& 6 beta
US5885800A (en) * 1997-02-04 1999-03-23 Smithkline Beecham Corporation DNA encoding tumor necrosis related receptor, TR4
AU9013998A (en) * 1997-07-21 1999-02-10 Zymogenetics Inc. Tumor necrosis factor receptor ztnfr-5
EP1019502A2 (fr) * 1997-08-06 2000-07-19 Regeneron Pharmaceuticals, Inc. Nouveau recepteur orphelin
EP1015587B1 (fr) * 1997-09-18 2008-04-23 Genentech, Inc. HOMOLOGUE DU TNFR APPELE POLYPEPTIDE DcR3
AU1535699A (en) * 1997-11-24 1999-06-15 Apotech S.A. Novel receptors opg-2
AU3369199A (en) * 1998-03-30 1999-10-18 Eli Lilly And Company Therapeutic applications of mature flint (mflint) polypeptides or opg3, a memberof the tnf receptor superfamily

Also Published As

Publication number Publication date
WO2000037094A3 (fr) 2000-11-09
JP2003520761A (ja) 2003-07-08
AU2211100A (en) 2000-07-12
EP1140138A2 (fr) 2001-10-10
WO2000037094A2 (fr) 2000-06-29

Similar Documents

Publication Publication Date Title
US20040167074A1 (en) Therapeutic applications of mFLINT polypeptides
Brines et al. Erythropoietin‐mediated tissue protection: reducing collateral damage from the primary injury response
EP0885299B1 (fr) Recepteur et ligands ob
JP4411330B2 (ja) 腫瘍壊死因子関連リガンド
EP1326974B1 (fr) Procedes relatifs a l'utilisation de polypeptide lie a l'interleukine 17 (il-17) humaine pour le traitement de maladies-
JP3750819B2 (ja) Ｃ−ｋｉｔ受容体に対するリガンド及びその使用法
WO1997047321A1 (fr) Utilisation de proteines chimeres regulatrices du complement du virus vaccinal pour inhiber ledit complement
US6475781B1 (en) Trans-dominant suppressor genes for oligomeric proteins
JP2005506287A5 (fr)
CA2181566C (fr) Compositions et methodes utilisant un recepteur mpl non lie pour stimuler la production de plaquettes
JP2005506287A (ja) 造血障害を治療するためのｌｐ８２の使用
US20020069422A1 (en) New polypeptides and peptides, nucleic acids coding for them, and their use in the field of tumor therapy, inflammation or immunology
CA2358508A1 (fr) Applications therapeutiques de polypeptides flint
US6207454B1 (en) Method for enhancing the effciency of gene transfer with stem cell factor (SCF) polypeptide
US7537932B1 (en) Antibodies that bind purified mammalian FLT3 ligands
EP0977859B1 (fr) Facteur neurotrophique nnt-1
ZA200005157B (en) Therapeutic applications of mature flint (mFLINT) polypeptides or OPG3, a member of the TNF receptor superfamily.
US20040236088A1 (en) Novel polypeptide analogs and fusions and their methods of use
MXPA00009523A (en) THERAPEUTIC APPLICATIONS OF MATURE FLINT (mFLINT) POLYPEPTIDES OR OPG3, A MEMBER OF THE TNF RECEPTOR SUPERFAMILY
WO2001028582A2 (fr) Applications therapeutiques de polypeptides de flint
RU2258710C2 (ru) Новый цитокин zalpha11-лиганд
US20040072745A1 (en) Therapeutic methods of use for lp229
KR100409099B1 (ko) 신경 손상 치료 기구
WO1998055141A9 (fr) Procedes et produits pour induire l'apoptose des cellules neuroendocrines a l'aide de proteine stimulant les macrophages
WO2003065981A2 (fr) Methodes d'utilisation therapeutiques de lp229

Legal Events

Date Code Title Description
FZDE Dead